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INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is the most com-
mon type of non-Hodgkin’s lymphoma in Western countries,
and accounts for approximately 60% of patients with B-cell
lymphomas in East Asia (1, 2). Although these tumors are
designated as a single disease entity by the World Health
Organization (WHO), the diversity of clinical presentations
and pathologic, genetic, and molecular characteristics strong-
ly suggest that these neoplasms represent a heterogenous
group of tumors (3). Despite the use of anthracyclin-based
chemotherapy, long-term disease-free survival can only be
achieved in about 40% of patients (1). Therefore, it is impor-
tant to identify the patients who may benefit from more agg-
ressive or experimental therapies at diagnosis.
Alizadeh et al. recently reported that DLBCL can be divid-
ed into prognostically significant subgroups with germinal
center B-cell-like (GCB), activated B-cell-like (ABC), or type
3 gene expression profiles using cDNA microarray (3). The
GCB group had a significantly better survival rate than the
ABC group (3). The type 3 group was heterogeneous and not
well defined, but had a poor outcome similar to the ABC gro-
up (3). Their results have been confirmed by another study
demonstrating that the gene expression profiles predict the
survival of DLBCL patients after chemotherapy (4). 
More recently, there have been several studies subdividing
DLBCLs into prognostically important subgroups by using
an immunohistochemical panel (5-9). However, the resulting
data have been controversial, with several studies showing a
significantly better survival rate for the GCB group and oth-
ers finding no difference in survival between the GCB and
non-GC groups (5-9).
The aim of this study was to investigate the expression of
CD10, Bcl-6, MUM1, CD138, and Bcl-2 in nodal DLBCLs,
and to analyze the relationship between immunohistochemi-
cal profile and outcome in nodal DLBCLs. Thus, we also eval-
uated the use of an immunohistochemical profile to subdivide
DLBCLs into prognostically significant subgroups by using
germinal center B-cell (CD10 and Bcl-6) and activation (MU-
M1 and CD138) markers with a tissue microarray (TMA).
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Prognostic Evaluation of Nodal Diffuse Large B Cell Lymphoma by
Immunohistochemical Profiles with Emphasis on CD138 Expression as
a Poor Prognostic Factor
Recently diffuse large B cell lymphoma (DLBCLs) was reported to be subdivided
into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subgroups
by using cDNA microarray and immunohistochemical markers. Tissue microarray
blocks were created from 51 nodal DLBCLs with control tissue. Immunohistochemi-
cal staining for the above markers were performed. The median follow-up period
was 26 months. Nodal DLBCLs were subclassified into GCB [CD10+ or CD10-/
Bcl-6+/MUM1-, n=17 (33%)] and non-GC subgroups [CD10-/Bcl-6- or CD10-/Bcl-
6+/MUM1+, n=35 (67%)], and were alternatively subclassified into pattern A [+ for
GCB marker only, n=12 (23%)], B [Co-positive for both markers, n=13 (33%)], C
[+ for activation marker only, n=18 (35%)], and D [- for both markers, n=9 (17%)].
Upon survival analysis, the GCB groups showed a relatively better survival than
non-GC groups (p=0.0748). Also, pattern C (p=0.0055) and CD138+ (p=0.0008)
patients had significantly lower survival rates. By multivariate analysis, CD138 expres-
sion alone was considered as an independent risk factor (p=0.031). In summary, our
results add to the registration of prognostic implications for previously reported DL-
BCL subgroups. CD138 may play an important role as a poor prognostic marker. By
using immunohistochemistry, a prognostically important subclassification of DLB-
CLs is possible.
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MATERIALS AND METHODS
Patient population
The study group consisted of 51 patients with de novo nodal
DLBCLs including five patients with de novo tonsillar DLB-
CLs diagnosed at Hanyang University Medical Center from
1995 to 2002, and classified according to WHO criteria based
on morphological examination of imprints, paraffin sections,
and immunophenotyping. 
Tissue microarray and immunohistochemical staining
Hematoxylin and eosin-stained sections from each paraf-
fin-embedded, formalin-fixed block were used to define diag-
nostic areas. In addition, two random, representative 0.6 mm
cores were obtained from each case and inserted in a grid pa-
ttern into a recipient paraffin block using a tissue arrayer (Be-
echer Instruments, Silver Spring, MD, U.S.A.). For the con-
trol group, three cases of follicular lymphoma and three cases
of reactive tonsil were included in each TMA block. Four- m
sections were then cut from each TMA block and stained
with antibodies to CD10, Bcl-6, MUM1, CD138, Bcl-2, and
MIB1, as listed in Table 1, using the avidin-biotin method.
Each core was evaluated independently by two pathologists
for the percentage of tumor cells stained by visual estimation,
and recorded in 10% increments. Disagreements were resol-
ved by joint review on a multihead microscope. For each case,
the core with the highest percentage of stained tumor cells
was used for analysis. For CD10, Bcl-6, Bcl-2, MUM-1 and
CD 138, cases were considered positive if 30% or more of
the tumor cells were stained with an antibody based on pre-
vious studies.
Subgrouping methods of DLBCLs
Immunoperoxidase results for CD10, Bcl-6, MUM1, and
CD138 were used to subclassify the patients. We divided the
DLBCLs into subgroups according to two different methods
proposed by Hans et al. and Chang et al., which are shown in
Table 2 (8, 9). According to Hans et al., patients were separat-
ed into GCB and non-GC groups (8). If CD10 was positive,
regardless of Bcl-6, MUM-1 or Bcl-6 status, DLBCLs were
subclassified as GCB. The remaining patients were classified
as non-GC. However, according to Chang et al. method, the
cases could be subclassified into four patterns: positive GCB
marker only (A), positive GCB and activation marker (B), pos-
itive activation marker only (C), and all negative (D) (9).
Statistical analysis
The Kaplan-Meier method was used to estimate overall
survival distributions. Overall survival was calculated from
the time from diagnosis to the date of death or last contact.
Patients who were alive at last contact were censored in the
overall survival analysis. The log-rank test was used to com-
pare the clinical characteristics between the TMA subgroups.
Univariate and multivariate analysis was performed using the
Cox regression method. Stepwise selection was used to deter-
mine variables that were independent predictors of overall
survival. The SPSS 11.0 Statistical software (U.S.A.) program
was used for data analysis. A value of p<0.05 was considered
as significant and 0.05≤p<0.10 as relatively significant.
RESULTS
Clinical data
Clinical data are summarized in Table 3, which represent
patients in GCB and non-GC subgroups. Clinical data for
survival analysis were available for 51 patients with a mini-
mum follow up period of 16 months. There were 30 males
and 21 females with a median age of 59 yr (age range, 19-83
yr). The median follow up period was 26 months. The clini-
cal features of the two DLBCL subgroups (GCB vs. non-GC)
did not differ in any regard. Similarly, of the four patterns (A,
B, C, and D) observed, clinical parameters did not differ (data
not shown).
Antigen
Cut-
Antibody Clone Source
retrieval
Dilution off 
value
CD10 56C6 Ventana, U.S.A. Citrate/Autoclave 1:1 30%
BCL-6 PG-B6p Ventana, U.S.A. Citrate/Autoclave 1:1 30%
MUM1 MUM1p DAKO, Denmark Citrate/Autoclave 1:100 30%
CD138 MI15 DAKO, Denmark Citrate/Autoclave 1:100 30%
BCL-2 124 DAKO, Denmark Citrate/Autoclave 1:50 30%
Ki-67 MIB-1 DAKO, Denmark Citrate/Autoclave 1:100 Nu-
merical
Table 1. Antibodies used for immunohistochemical staining
Two subgroups of DLBCLs according to Hans et al. (8)
Subgroup CD10 BCL-6 MUM1 CD138
GCB + Any Any Any
- + - Any
Non-GC - - Any Any
-++ N D
Pattern CD10 BCL-6 MUM1 CD138
A + and/or + - -
B + and/or + + and/or +
C - - + and/or +
D ----
Four patterns of DLBCLs according to Chang et al. (9)
Table 2. Subgrouping methods for DLBCLsExpression of CD10, Bcl-6, CD138, MUM1, and Bcl-2
Out of the total 51 patients, 11 (22.0%, except for one un-
determined patient) were positive for CD10, 20 (39.2%) for
Bcl-6, 23 (45.1%) for Bcl-2, 16 (31.4%) for MUM1, and 8
(15.7%) for CD138. When the patients were subdivided ac-
cording to the two different methods stated above, 21 patients
(42.0%, except for one patient with undetermined CD10 sta-
tus) were subclassified as GCB and 29 (58.0%) as non-GC.
Using the four group classification, 17 patients (33.3%) were
subclassified as pattern A, seven (13.7%) as B, 14 (27.5%) as
C, and 13 (25.5%) as D.
Survival analysis
Tumor expression of CD10 was associated with better over-
all survival, which was relatively significant (p=0.0992, Fig.
1A). On the other hand, tumor expression of Bcl-6 also tend-
ed to convey better survival, but not to a significant level (p=
0.2509, Fig. 1B). MUM1 expression did not result in any dif-
ference in overall survival between the two groups (p=0.5207,
Fig. 2A). In contrast, CD138 positive patients showed a stri-
kingly worse overall survival rate, although there were only
eight patients in total (p=0.0008, Fig. 2B). No significant
difference in survival was found between the Bcl-2 positive
and negative groups (p=0.5307, not shown). In view of the
International Prognostic Index, the low IPI group showed a
better survival, which was relatively significant in our study
(p=0.0978, data not shown). 
When we divided patients into GCB and non-GC subgro-
ups, the GCB subgroup showed a better survival rate than the
non-GC subgroup at a relatively significant level (p=0.0748,
Fig. 3A). When separately considering patients with low or
high IPI scores, the GCB groups also had a better survival
rate than the non-GC subgroup with low (p=0.5307, Fig. 3B)
and high IPI scores (p=0.1534, Fig. 3C). On the other hand,
when we divided the patients into patterns A, B, C, and D,
pattern C showed a strikingly poor survival. In contrast, there
were no remarkable differences among patterns A, B, and D.
When we divided them into two groups, pattern C had a
significantly lower survival rate compared to pattern A or B
(Fig. 4A). Furthermore, when separately considering those
patients with low (Fig. 4B) or high IPI scores (Fig. 4C), four
pattern C patients with high IPI scores had a strikingly lower
survival than others.
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Stt, Student t-test; Srt, Spearman’s rho test.
Total (%) GCB (%)
Non-GC 
Statistics p
(%)
Total No. 76 27 (36%) 49 (64%)
Age (yr)
Median 59 51 59 Stt 0.11
Range 19-83 19-80 31-83
Stage
I/II 41 (60%) 15 (60%) 25 (60%) Srt 0.97
III/IV 27 (40%) 10 (40%) 17 (40%)
Extranodal sites
Fewer than 2 59 (92%) 22 (88%) 36 (95%) Srt 0.34
2 or more 5 (8%) 3 (12%) 2 (5%)
Karnofsky score
Higher than 70 13 (19%) 4 (21%) 9 (30%) Srt 0.56
70 or lower 54 (81%) 15 (79%) 21 (70%)
LDH
Normal  41 (69%) 14 (64%) 27 (75%) Srt 0.37
High 18 (31%) 8 (36%) 9 (25%)
IPI risk group
Low 0-2 35 (61%) 14 (64%) 20 (83%) Srt 0.73
Table 3. Clinical characteristics of 76 patients with diffuse large
B-cell lymphomas and statistical comparison between GCB
and non-GC subgroups
Fig. 1. Kaplan-Meier survival analysis in DLBCL according to CD10 (A) and Bcl-6 expression (B). (A) Patients with CD10 expression above
30% demonstrate significantly better survival. (B) Patients with Bcl-6 expression above 30% tend to have a relatively better survival, but not
at a significant level.
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By univariate Cox proportional hazards regression analysis,
our results showed that expression of the individual CD138
marker and pattern C was associated with an increased rela-
tive risk of death in DLBCL patients (Table 4). Moreover, CD
Fig. 2. Kaplan-Meier survival analysis in DLBCL according to MUM1 (A) and CD138 expression (B). (A) MUM1 expresssion does not influ-
ence the overall survival between positive and negative groups. (B) Patients with CD138 expression show a strikingly worse overall survival,
although there were only eight positive cases.
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Fig. 3. Kaplan-Meier survival analysis in DLBCL between GCB and
non-GC subgroups. (A) The GCB subgroup demonstrates a lon-
ger survival than the non-GC subgroup. (B, C) When separately
considering patients with low or high IPI scores, the GCB groups
possess a longer survival in both low (B) and high IPI score gro-
ups (C).
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10 expression, GCB subgroup classification, and IPI scores
made relatively significant impacts on survival. Most impor-
tantly, using a multivariate Cox proportional hazards regres-
sion analysis, only the expression of CD138 alone was statis-
tically significant as an independently poor prognostic factors,
controlling for IPI status (Table 5). 
Characteristics of patients with CD138 expression
CD138 was expressed in eight of the 51 DLBCL patients.
The clinical and immunohistochemical characteristics of all
eight patients with CD138 expression are summarized in
Table 6. Six patients were negative for germinal center B cell
markers. However, one patient was positive for both CD10
and Bcl-6 (Fig. 5), and another patient for Bcl-6 alone. These
patients were classified into subgroups B and GCB, respec-
tively. The first 80-yr-old male patient expired six months
later. In contrast, the second 28-yr-old female patient, who
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Fig. 4. Kaplan-Meier survival analysis in DLBCL among patterns
A, B, and C. (A) The overall survival rate curve of pattern C shows
a significantly lower survival rate compared to patterns A and B.
(B, C) When separately considering those patients with low or high
IPI scores, pattern C also shows a strikingly poor survival rate in
both low (B) and high IPI score groups (C).
A & B, n=24
C, n=14
A & B, n=14
C, n=5
A & B, n=5
C, n=4
Lower Upper
bound bound
95% Confidence
Interval for RR
Table 4. Univariate Cox proportional hazards regression analysis
RR, Relative risk.
CD10 positive/negative 11/39 0.102 0.567 0.168 1.919
Bcl-6 positive/negative 20/31 0.262 0.600 0.246 1.463
CD138 positive/negative 8/43 0.002 3.855 1.663 10.032
MUM1 positive/negative 16/35 0.551 1.299 0.550 3.069
BCL-2 positive/negative 23/14 0.432 0.681 0.262 1.774
GCB/Non-GCB 21/29 0.097 0.451 0.176 1.156
pattern A or B/pattern C 24/14 0.010 0.278 0.105 0.735
Low IPI/High IPI 23/12 0.123 0.434 0.150 1.255
Lower Upper
bound bound
95% Confidence
Interval for RR
Table 5. Multivariate Cox proportional hazards regression analysis
RR, Relative risk.
CD138 positive/negative 8/43 0.031 3.858 1.128 13.196
CD10 positive/negative 11/39 0.370 0.587 0.158 3.911
Low IPI/High IPI 23/12 0.192 0.480 0.153 1.510
Variable
No. of
p RR
cases
Variable
No. of
p RR
caseshad received bone marrow transplantation, was still alive at
follow up 68 months later. The remaining six patients were
subclassified as pattern C and non-GCB. These patients died
in a relatively short period. Most of the patients with CD138
expression showed generally high Ki-67 labeling indices.
DISCUSSION
TMA is a useful and cost-effective tool that allows rapid
evaluation of immunohistochemical staining of a large num-
ber of tumors simultaneously (10). TMA appears to be par-
ticularly useful for the immunohistochemical characteriza-
tion of malignant lymphomas (10). The TMA immunostain-
ing results have been shown to agree with whole tissue sec-
tion staining in 86% to 100% of patients (11). When com-
pared with whole section immunohistochemistry, TMA de-
monstrates superior immunostaining consistency between
cases because most cases are located on the same TMA sec-
tion (10). Quantitation of the staining results is also easier
402 Y.-H. Oh, C.-K. Park
Sex CD10 BCL-6 MUM1 CD138 BCL-2 Ki-67 (%) GC/NG Pattern IPI FU (mon) Survival Age (yr)
1 M 80 + + - + - 80 GCB B ND 6 Death
2 F 28 - + - + - 50 GCB B High 68 Alive*
3 M 69 - - - + + 20 NG C High 4 Death
4 F 60 - - - + - 80 NG C ND 13 Death
5 F 32 - - + + + 70 NG C High 1 Death
6 M 74 - - + + + 30 NG C High 3 Death
7 M 82 - - + + - 80 NG C Low 20 Death
8 M 42 - - - + - 95 NG C Low 16 Death
Table 6. Summary of patients with CD138 expression
GC/NG, GCB subgroup vs. non-GC subgroup. FU, follow-up. *, This patient received bone marrow transplantation for treatment.
Fig. 5. Histologic and immunohistochemical findings of an 80-yr-old male CD138 positive patient (case 1). (A) Histologic findings of DLBCL
patient 1. (B, C, D, E) Tumor cells were diffusely positive for CD138 (B: ×40, C: ×200), CD10 (D: ×200), and BCL-6 (E: ×200). This pa-
tient died within six months.
A B C
D Ebecause each tissue core can be completely viewed under one
intermediate-power microscopic field. Furthermore, the use
of TMA preserves the tissue in the paraffin blocks for future
studies. In the present study, we selected two different, rela-
tively well preserved and representative areas from each tumor
for use in the TMA blocks. Thus, we could easily and consis-
tently evaluate the immunohistochemical staining results.
The diversity in the clinical presentation, morphology, im-
munophenotype, and genetic and molecular alterations stro-
ngly suggests that DLBCL is a heterogenous group of B-cell
lymphomas rather than a single clinicopathologic entity (12-
14). The primary site of the lymphoma, either the lymph node
or different extranodal territories, has been suggested as a
criterion that might distinguish the two different groups of
DLBCL, nodal and extranodal, with particular clinicobiologi-
cal characteristics and different natural history (15, 16). How-
ever, the current classification of lymphomas is largely based
on the clinicopathologic features and, at present, does not take
into consideration the primary site of the lymphoma; it is
simply regarded as additional information (12). In the pre-
sent study, 69 patients with primary de novo nodal DLBCLs
were selected for a uniform study population. In general, Wal-
deyer’s ring, whose lymphoid tissue is similar to that of the
lymph node, is currently included among nodal areas (16).
Therefore, we also included seven DLBCLs of the Waldeyer’s
ring in the present study.
CD10 is a human membrane associated neutral endopep-
tidase, and antibodies against CD10 embedded in paraffin
sections are available (17). CD10 is expressed in a variety of
human tissues, but its expression is restricted in the germi-
nal center cells of reactive lymphoid tissues (17). There have
been several studies examining CD10 expression in DLBCLs
by immunohistochemistry, but the resulting data are conflict-
ing (6-9, 18-24). Chang et al. and Ohshima et al. have report-
ed that CD10 expression is associated with a better DLBCL
prognosis (9, 19). In contrast, Uherova et al. and Xu et al.
have suggested that CD10 expression is associated with poor
outcome (21, 24). In the present study, patients with CD10
expression showed a better survival rate at a marginally sig-
nificant level (p=0.0992). 
Bcl-6 is a zinc-finger protein that acts as a transcriptional
repressor and is expressed in germinal center B cells and a sub-
set of CD4+ T cells (25, 26). Immunohistochemical studies
of Bcl-6 expression and its relationship to DLBCL patient
outcomes are limited in number. Hans et al. reported Bcl-6
expression evaluated by immunohistochemistry to be associ-
ated with a better prognosis (8). Likewise, other studies have
reported that Bcl-6 expression predicts a better overall sur-
vival, whereas another study found no difference in overall
survival related as to Bcl-6 expression (6, 8, 9, 27). Our results
demonstrated that patients with Bcl-6 expression tended to
show better survival, but not at a statistically significant level
(p=0.2509).
Regarding the prognostic value of Bcl-2 expression in DL-
BCLs, most studies have shown no difference in prognosis
between Bcl-2 positive and negative patients, whereas a recent
study by Biasoli et al. suggested that Bcl-2 expression, espe-
cially in the high IPI group, is associated with a significantly
decreased survival (8, 22, 28, 29). Our results show no differ-
ence in survival between Bcl-2 positive and negative groups,
similar to the results of most previous studies, except for Bia-
soli et al. (22). 
MUM1/IRF-4 (multiple myeloma-1/interferone regulato-
ry factor-4) is a lymphoid specific member of the interferon
regulatory factor family of transcription factors, and is nor-
mally expressed in plasma cells and a minor subset of germi-
nal center cells (30, 31). Studies have shown that MUM1 ex-
pression may denote the late stage of germinal center B-cell
differentiation (3, 30, 31). Moreover, Hans et al. reported that
MUM1 expression identified non-GCB patients (8). Thus, we
used MUM1 as an activated B cell marker in the present study.
Prognostic significance of MUM1 expression in DLBCL pa-
tients has been limited. Hans et al. and Chang et al. reported
that expression of MUM1 is associated with a significantly
worse survival (8, 9). However, our results demonstrate no
difference in survival between MUM1 positive and negative
groups.
CD138, also known as syndecan-1, is expressed in antigen-
stimulated B cells and denotes terminal differentiation toward
plasma cells (32). The clinical significance of CD138 expres-
sion in DLBCL patients has not been well documented. In
the present study, patients with CD138 expression showed
a strikingly worse survival. However, there were only eight
CD138 positive cases. 
Recently, there have been several efforts to classify DLBCL
patients into prognostically implicated subgroups using cDNA
microarray and immunohistochemical expression profiles (3,
6-9). However, the methods remain controversial. As a part
of the efforts to classify DLBCL patients into prognostically
implicated subgroups, the present study used an immunohis-
tochemical panel of GCB-cell and activation markers as stat-
ed above, such as CD10, Bcl-6, MUM1, and CD 138, on pa-
raffin-embedded tissues. Hans et al. reported that the expres-
sion of CD10, Bcl-6, and MUM1 can be combined to divide
DLBCL patients into GCB and non-GC subgroups with out-
comes similar to that predicted by cDNA microarray analy-
sis as they have previously reported (8). Chang et al. also re-
ported that the expression patterns of CD10, Bcl-6, MUM1/
IRF4, and CD138 of GCB cell and activation markers by im-
munohistochemistry correlate with the prognosis of DLBCL
patients (9). Similarly, Biasoli et al. reported that the expres-
sion of CD10 could predict a favorable outcome, especially
in the low-risk IPI group, and the expression of Bcl-2 was an
independent poor prognostic factor (22). In contrast, Colomo
et al. reported that a differentiation profile using CD 10, Bcl-
6, MUM1, and CD138 was associated with particular clini-
copathological features, but was not essential for predicting
DLBCL patient outcome (6). More recently, Fabiani et al. re-
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survival (23). In the present study, patients in the GCB group
showed a relatively better overall survival rate than those in
the non-GC subgroup (p=0.0748). Similarly, patients sub-
classified as pattern C (CD10-, Bcl-6-/MUM1+ or CD138+)
showed a significantly lower survival rate than pattern A (CD
10+ or Bcl-6+/MUM1-, CD138-) or B patients (CD10+ or
Bcl-6+/MUM1+ or CD138+) (p=0.0055). Our results further
support that immunohistochemical expression profiles using
CD10, Bcl-6, MUM1, and CD138 could predict DLBCL pa-
tient outcome.
More interestingly, patients with CD138 expression showed
a strikingly worse survival. Upon univariate and multivari-
ate analysis, CD138 expression proved to be an independent
poor prognostic factor regardless of IPI status. Even though
expression pattern C proved to be an independent poor prog-
nostic factor, it was largely influenced and dependent on CD
138 expression. Thus, its prognostic importance needs to be
mentioned in conjunction with that of CD138 expression.
As shown in Table 6, six patients of eight patients showing
CD138 expression were negative for germinal center B cell
markers. Thus, they were subclassified into the non-GC and
pattern C groups. However, one patient was positive for both
CD10 and BCL-6, and another patient for BCL-6 alone. These
patients were subclassified into the GCB and pattern B gro-
ups. In particular, an 80 yr-old male patient (patient 1) as
shown in Table 6 expired at six months. In contrast, a 28-yr-
old female patient (patient 2) was still alive at follow up 68
months later. After a more detailed search for clinical infor-
mation about this patient, the authors discovered that she
received bone marrow transplantation after her DLBCL diag-
nosis. The remaining six patients in the non-GC and pattern
C groups all expired in relatively short period (patients 3-8).
Colomo et al. reported that CD138 is highly expressed in the
plasmablastic variant of DLBCL, the so-called plasmablastic
lymphoma, which is usually associated with HIV infection,
and has a highly aggressive clinical behavior (33). Plasmablas-
tic lymphoma was characterized by immunoblastic morphol-
ogy and a plasma cell phenotype with absent or weak B-cell
markers and strong reactivity for plasma cell associated anti-
gens. Patients with CD138 expression in the present study
might be diagnosed with plasmablastic lymphoma. Howev-
er, all eight CD138 expression tumors did not show the mor-
phologic criteria of plasmablastic lymphoma upon histologic
review. They were also diffusely and strongly positive for B-
cell markers such as CD20 and CD79a. Moreover, despite a
diligent search for clinical records of all patients with CD138
expression, there was no evidence of HIV-1 infection or immu-
nosuppression. Thus, the possibility of plasmablastic lym-
phoma having an aggressive clinical behavior could be ruled
out. Therefore, our results suggest that CD138 expression
may play an important role in clinical outcome as a poor prog-
nostic factor. Unfortunately, CD138 expression has been re-
ported at an extremely low expression rate, as shown by the
present study.
In conclusion, our results add to the registration of prog-
nostic implications of previously reported DLBCL subgroups.
In addition, CD138 may play an important role as a poor
prognostic marker. Further investigations examining CD138
expression that include more patients are necessary to reach
more specific conclusions. Finally, by using an immunohisto-
chemical panel for CD10, BCL-6, MUM-1, and CD138 ex-
pression, prognostically important subclassification of DLBCL
patients was attained.
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